What is Otrivin-S?
Otrivin-S is the chemical name for salt. Otrivin-S can reduce some types of bacteria in certain body secretions, such as saliva.
Otrivin-S inhalation is used to produce sputum (mucus, or phlegm) from the mouth to help improve lung function in people with cystic fibrosis, or to collect sputum for medical testing. This medication may also be used to dilute other medications inhaled through a nebulizer.
Otrivin-S inhalation may also be used for other purposes not listed in this medication guide.
Otrivin-S indications
Airlife Modudose Otrivin-S as isotonic solution: the dehydration of various origins. To maintain the volume of blood plasma during and after surgery. As a solvent for various drugs.
Hypertonic solution: violations of water-electrolyte metabolism: lack of sodium and chlorine ions; hypoosmotic dehydration of various origins (due to prolonged vomiting, diarrhea, burns with a gastric fistula, pulmonary hemorrhage, intestinal bleeding).
Eye drops and ointment: irritation of the cornea with inflammatory and allergic diseases (combined therapy).
How should I use Otrivin-S?
Use Otrivin-S nebulizer solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Otrivin-S nebulizer solution is for inhalation in a nebulizer only. Do not take Otrivin-S nebulizer solution by mouth or inject it.
- Otrivin-S nebulizer solution is used to dilute other medicines. Follow the instructions provided by your doctor.
- Otrivin-S nebulizer solution may come in a single-dose vial or in a container with multiple doses. Be sure to use the proper amount of Otrivin-S nebulizer solution. If you are using Otrivin-S nebulizer solution from a multiple-dose container, use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- If you are using a vial, use your dose immediately after opening the vial and throw away any unused medicine. Do not save the contents of an opened vial for later use.
- Do not use Otrivin-S nebulizer solution if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
- This product is intended to dilute other medicines for use in a nebulizer. If you miss a dose of your medicine, follow the missed dose instructions for the medicine that you are mixing with this product.
Ask your health care provider any questions you may have about how to use Otrivin-S nebulizer solution.
Uses of Otrivin-S in details
This product is used to treat dryness inside the nose (nasal passages). It helps add moisture inside the nose to dissolve and soften thick or crusty mucus. In babies and young children with stuffy noses who cannot blow their noses, using this product helps to make the mucus easier to remove with a nasal bulb syringe. This helps relieve stuffiness and makes breathing easier.
This product contains a purified gentle salt solution (also called saline or Otrivin-S solution). It does not contain any medication.
How to use Otrivin-S nasal
Spray this product into each nostril as needed or as directed by your doctor. This product may also be given into the nose as drops or a stream. Follow all directions on the product package. If you are uncertain about any of the information, consult your doctor or pharmacist.
Try not to touch the container tip to the inside of your nose. If this happens, rinse the tip with hot water and dry with a clean tissue before recapping the container.
If your condition persists or worsens, or if you think you may have a serious medical problem, seek immediate medical attention.
Otrivin-S description
Otrivin-S, also known as salt, common salt, table salt or halite, is an ionic compound with the chemical formula NaCl, representing a 1:1 ratio of sodium and chloride ions. Otrivin-S is the salt most responsible for the salinity of seawater and of the extracellular fluid of many multicellular organisms. It is listed on the World Health Organization Model List of Essential Medicines.
Otrivin-S dosage
All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile and nonpyrogenic equipment.
As directed by a physician. Dosage, rate, and duration of administration are to be individualized and depend upon the indication for use, the patient’s age, weight, clinical condition, concomitant treatment, and on the patient’s clinical and laboratory response to treatment.
When other electrolytes or medicines are added to this solution, the dosage and the infusion rate will also be dictated by the dose regimen of the additions.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions, where possible.
Do not administer unless the solution is clear and seal is intact.
Additives may be incompatible with Otrivin-S Injection, USP. As with all parenteral solutions, compatibility of the additives with the solution must be assessed before addition. Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of Otrivin-S Injection, USP is appropriate. After addition, check for unexpected color changes and/or the appearance of precipitates, insoluble complexes or crystals.
The instructions for use of the medication to be added and other relevant literature must be consulted. Additives known or determined to be incompatible must not be used. When introducing additives to Otrivin-S Injection, USP, aseptic technique must be used. Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives.
After opening the container, the contents should be used immediately and should not be stored for a subsequent infusion. Do not reconnect any partially used containers. Discard any unused portion.
Otrivin-S interactions
See also:
What other drugs will affect Otrivin-S?
Caution must be exercised in the administration of Otrivin-S Injection, USP to patients receiving corticosteroids or corticotropin.
Studies have not been conducted to evaluate additional drug/drug or drug/food interactions with Otrivin-S (Otrivin-S (Otrivin-S injection) injection) Injection, USP.
Otrivin-S side effects
See also:
What are the possible side effects of Otrivin-S?
Post-Marketing Adverse Reactions
The following adverse reactions have been identified during postapproval use of Otrivin-S Injection, USP. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been reported in the post-marketing experience during use of 0.9% Otrivin-S Injection, USP and include the following:
hypersensitivity/infusion reactions, including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus.
Also reported are infusion site reactions, such as infusion site erythema, injection site streaking, burning sensation, and infusion site urticaria.
The following adverse reactions have not been reported with 0.9% Otrivin-S Injection, USP but may occur: hypernatremia, hyperchloremic metabolic acidosis, and hyponatremia, which may be symptomatic.
Hyponatremia has been reported for 0.45% Otrivin-S Injection, USP.
The following adverse reactions have not been reported with 0.45% Otrivin-S Injection, USP but may occur: hyperchloremic metabolic acidosis, hypersensitivity/infusion reactions (including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus), and infusion site reactions (such as infusion site erythema, injection site streaking, burning sensation, infusion site urticaria).
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Otrivin-S contraindications
See also:
What is the most important information I should know about Otrivin-S?
Due to potential toxicity of benzyl alcohol in newborns, Bacteriostatic Otrivin-S Injection, USP, 0.9% containing benzyl alcohol must not be used in this patient population.
Bacteriostatic Otrivin-S Injection, USP, 0.9% should not be used for fluid or Otrivin-S replacement.
Active ingredient matches for Otrivin-S:
Sodium chloride in India.
| Unit description / dosage (Manufacturer) | Price, USD |
| 0.74 % w/v x 10ml | $ 0.30 |
| Otrivin-S 0.74% w/v N-DPS / 10ml | $ 0.30 |
| OTRIVIN-S nasal spray 0.74 % w/v x 10ml (Novartis (OTC)) | $ 0.45 |
| Otrivin-S 0.74% w/v N-DPS / 10ml | $ 0.30 |
List of Otrivin-S substitutes (brand and generic names): | |
| Otrivin Sea Water (Australia) | |
| Otrivini (Israel) | |
| Spray; Nasal; Sodium Chloride 0.74% (Novartis consumer) | |
| Otrivini Saline for Babies | |
| Spray; Nasal; Sodium Chloride 0.74% | |
| Otsu-NS (Indonesia) | |
| Otsu-NS 100 mL x 1's (Otsuka) | |
| Otsu-NS 250 mL x 1's (Otsuka) | |
| Otsu-NS 500 mL x 1's (Otsuka) | |
| Otsu-NS 1 L x 1's (Otsuka) | |
| PD-LYTE-E (India) | |
| 500ml (Parenteral Drugs) | $ 0.43 |
| Pd-Lyte-E Sodium chloride 0.5 g, anhydrous dextrose 5 g, magnesium chloride 0.031 g, potassium chloride 0.075 g, calcium chloride 0.052 g, sodium metabisulphite 0.02 g, sodium acetate 0.64 g, sodiumcitrate 0.075 g/100 mL. INF / 500ml (Parenteral Drugs) | $ 0.43 |
| PD-LYTE-E infusion 500ml (Parenteral Drugs) | $ 0.43 |
| Pd-Lyte-E Sodium chloride 0.5 g, anhydrous dextrose 5 g, magnesium chloride 0.031 g, potassium chloride 0.075 g, calcium chloride 0.052 g, sodium metabisulphite 0.02 g, sodium acetate 0.64 g, sodiumcitrate 0.075 g/100 mL. INF / 500ml (Parenteral Drugs) | $ 0.43 |
| PECTOKAB-ORS (India) | |
| 5x6.53g (Chemage) | $ 0.14 |
| Pectokab-Ors Sodium chloride 0.25 g, anhydrous dextrose 5.4 g, sodium citrate 0.589 g, potassium chloride 0.3 g. POWD / 6.53 (Chemage) | $ 0.03 |
| Pectokab-Ors Sodium chloride 0.25 g, anhydrous dextrose 5.4 g, sodium citrate 0.589 g, potassium chloride 0.3 g. POWD / 6.53 (Chemage) | $ 0.03 |
| Pedi-Ors (India) | |
| Pedi-Ors Sodium chloride 0.52 g, potassium chloride 0.3 g, sodium citrate 0.58 g, anhydrous dextrose 2.7 g. POWD / 4.4g (Olcare (Paed Care)) | $ 0.07 |
| Pediasea (Chile) | |
| Solution; Nasal; Sodium Chloride 0.9% (Pediapharm) | |
| PEDITRAL-5.9 (India) | |
| 1's (RPG LS) | |
| Peditral-5.9 Sodium chloride 0.7 g, potassium chloride 0.3 g, sodium citrate 0.58 g, anhydrous dextrose 4 g/5.9 g. POWD / 5.9g (RPG LS) | |
| Peditral-5.9 Sodium chloride 0.7 g, potassium chloride 0.3 g, sodium citrate 0.58 g, anhydrous dextrose 4 g/5.9 g. POWD / 5.9g (RPG LS) | |
| Pekana - Natrium Muriaticum | |
| Drops; Oral; Sodium Chloride 6 c | |
| Globules; Oral; Sodium Chloride 6 c | |
| PF Drops Sodium Chloride (United Kingdom) | |
| Phy-O (Greece) | |
| Phybag (Netherlands, Sweden) | |
| Phylarm (Mexico) | |
| Physio (Georgia) | |
| Physiodose (Malaysia) | |
| Physiodose 0.9 % x 5 mL x 12's (Gilbert) | $ 33.50 |
| Physiodose 0.9 % x 1's (Gilbert) | |
| Drops; Nasal, Ophthalmic; Sodium Chloride 0.9% (Gilbert) | |
| Physiodose eye/ear/nose drops 0.9 % 1's (Gilbert) | |
| Physiol (Tunisia) | |
| Physiologic (Switzerland) | |
| Physiologica (France) | |
| Physiologica gifrer (Turkey) | |
| Physiological Saline | |
| Injectable; Injection; Sodium Chloride 0.9% | |
| Physiological serum Physiodose | |
| Physiologicasol (Belgium) | |
| Physiologische Kochsalzlösung Fresenius (Austria) | |
| Physionormi (Georgia) | |
| Physiophtal 0.9% | |
| Physiophtalfort 5% | |
| Physiorhine (Belgium) | |
See 1608 substitutes for Otrivin-S | |
References
- DailyMed. "AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "sodium chloride". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Sodium Chloride". http://www.drugbank.ca/drugs/DB09153 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Otrivin-S are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Otrivin-S. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
